Bicycle Therapeutics Plc - ADR

NASDAQ:BCYC  
59.54
-0.11 (-0.18%)
Products, Regulatory, Earnings Announcements

Bicycle Therapeutics Announces Interim BT5528 Phase I Trial Results, Prelim Results From BT8009 Phase I Clinical Trial

Published: 10/07/2021 17:02 GMT
Bicycle Therapeutics Plc - ADR (BCYC) - Bicycle Therapeutics Announces Interim Bt5528 Phase I Clinical Trial Results and Preliminary Results From Ongoing Bt8009 Phase I Clinical Trial.
Bicycle Therapeutics Plc - in Ongoing Bt8009 Phase I Trial in Monotherapy Cohorts, 4 Out of 11 Urothelial Patients Had Partial Responses.
Bicycle Therapeutics Plc - Bt5528 Phase I Anti-tumor Activity Observed in Late Line Patients.
Bicycle Therapeutics Plc - a Recommended Bt5528 Phase Ii Dose (rp2d) Range Has Been Established ; Expansion Cohorts Expected to Initiate in 2022.
Bicycle Therapeutics Plc - Look Forward to Providing Additional Clinical Data on Bt5528 and Bt8009 Next Year.
Bicycle Therapeutics Plc - Initiating Our Phase I/ii Study for Bt7480 Later This Year.
Bicycle Therapeutics Plc - Bt8009 Phase I Dose Escalation Remains Ongoing, With No Dose Limiting Toxicities (dlts) Yet Observed.
Bicycle Therapeutics Plc - Bt8009 Enrollment Ongoing.
Revenue is expected to be $5.63 Million
Adjusted EPS is expected to be -$0.61

Next Quarter Revenue Guidance is expected to be $4.79 Million
Next Quarter EPS Guidance is expected to be -$0.69

More details on our Analysts Page.